Patient organisations, allied health professionals, academia, corporate partners and a global health think-tank have come together to launch the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), a multisectoral coalition committed to improving heart health and reducing the CVD burden across nine countries in Asia (Australia, China, India, Indonesia, Japan, Malaysia, South Korea, Thailand, Vietnam). 

With four strategic partners – the Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB), Global Alliance for Patient Access (GAfPA), Global Heart Hub (GHH), and Universiti Teknologi MARA (UiTM) Faculty of Medicine in Malaysia – and corporate partners Amgen, Novartis, and Roche Diagnostics, the APAC CVD Alliance aims to increase public and policy awareness of the importance of tackling CVD at regional and domestic forums in Asia; encourage implementation of scalable and sustainable CVD innovations across all health systems in Asia, and emphasise that investments to address CVD is much needed for healthy societies and productive economies.

The APAC CVD Alliance will adopt a patient-centered approach across the entire CVD care continuum – prevention; early detection; treatment, cardiac rehabilitation, and step-down care.

Based in Singapore as its regional hub for Southeast Asia, global health think-tank ACCESS Health International is the secretariat for the APAC CVD Alliance.